The Bottom Line

Survival rates for skin cancer depend enormously on the type of cancer and how early it is found. Basal cell carcinoma and squamous cell carcinoma caught early are almost always curable — survival rates exceed 95–99%. Melanoma found early (stage I) has a 97% five-year survival rate. Advanced melanoma is more serious, but new immunotherapy and targeted therapy drugs have dramatically improved outcomes over the past decade, pushing two-year survival for stage IV melanoma from roughly 10% to 35–50%. Early detection remains the single most powerful tool.

Why Survival Rates Matter — and Their Limits

Survival statistics are based on large groups of patients and describe average outcomes. Your individual situation — your overall health, the exact features of your cancer, and the treatments available to you — may lead to a very different outcome. Survival rates are useful for understanding the landscape, not for predicting what will happen to you specifically.

The numbers below describe five-year survival rates, meaning the percentage of people who are alive five years after their diagnosis. Many people live much longer. And with rapidly improving treatments, newer patients often do better than historical statistics suggest.

Basal Cell Carcinoma (BCC) Survival

BCC is the most common skin cancer and the most easily treated. Five-year survival exceeds 99% even for advanced cases. Death from BCC is extremely rare — disease-specific mortality is less than 0.5%. BCC almost never spreads to other parts of the body.

The main risk with BCC is local damage — a tumor that grows into nearby bone, cartilage, or tissue around the eye or brain. Standard treatments (surgery, Mohs surgery, radiation) cure more than 95% of BCCs. Recurrence rates vary by subtype: nodular BCC recurs in about 5% of cases after proper treatment; infiltrative (morpheaform) BCC recurs in 10–20%.

Squamous Cell Carcinoma (SCC) Survival

SCC is the second most common skin cancer. For localized SCC — cancer that has not spread beyond the skin — five-year survival is 95–98%. The risk rises when SCC spreads to nearby lymph nodes or distant organs:

  • With one affected lymph node (stage IIIA): approximately 75% five-year survival
  • With multiple affected nodes (stage IIIB): approximately 50% five-year survival
  • With distant spread (stage IV): less than 25% five-year survival

Overall, 5–10% of SCCs spread (metastasize). Risk is much higher for large tumors (over 4 cm), poorly differentiated tumors, those with nerve invasion (perineural invasion), and tumors in people with weakened immune systems. Transplant recipients with SCC have significantly worse outcomes than the general population.

Melanoma Survival by Stage

Melanoma is the most serious skin cancer because of its ability to spread. But survival depends enormously on how early it is found:

Stage I — Localized, Thin Melanoma

  • Stage IA (thinner than 0.8 mm, no open sore): 97% five-year survival
  • Stage IB (0.8–1 mm thick, or any thickness with open sore): 92% five-year survival

Stage II — Localized, Thicker Melanoma

  • Stage IIA (1–2 mm thick): 81% five-year survival
  • Stage IIB (2–4 mm thick): 70% five-year survival
  • Stage IIC (thicker than 4 mm): 53% five-year survival

Stage III — Spread to Nearby Lymph Nodes

  • Stage IIIA (one microscopic node): 78% five-year survival
  • Stage IIIB (1–3 nodes with visible disease, or satellite lesions): 59% five-year survival
  • Stage IIIC (4 or more nodes, or extensive in-transit spread): 40% five-year survival

Stage IV — Spread to Distant Organs

Historically, stage IV melanoma had a five-year survival of just 7–15% with median survival of 6–12 months. However, modern immunotherapy and targeted therapy have transformed these numbers. Two-year survival now reaches 35–50% in patients treated with checkpoint inhibitor drugs — a dramatic improvement.

What Factors Affect Your Prognosis?

The single most important factor for melanoma is Breslow thickness — how deep the tumor has grown into the skin. Thicker tumors carry a significantly worse prognosis. Other key factors include:

  • Ulceration (open sore on the tumor surface): worsens prognosis at any thickness
  • Mitotic rate: how fast the cancer cells are dividing
  • Sentinel lymph node status: whether cancer has reached the first lymph node
  • BRAF mutation status: determines eligibility for targeted therapy
  • Circulating tumor DNA: an emerging test that can predict metastatic risk

For SCC, histologic grade (well vs. poorly differentiated), tumor size, and perineural invasion are the major prognostic factors.

How Modern Treatments Have Improved Survival

Immunotherapy (checkpoint inhibitors): Drugs like pembrolizumab (Keytruda) and nivolumab (Opdivo) activate your immune system to fight melanoma. For stage IV disease, checkpoint inhibitor monotherapy achieves 2-year overall survival of 40–50%, compared to just 10–15% historically. Combining two immunotherapy drugs (ipilimumab + nivolumab) pushes response rates to approximately 60%, though with more side effects.

Targeted therapy (BRAF/MEK inhibitors): About 40–50% of melanomas have a specific mutation called BRAF V600E. For these patients, combination BRAF/MEK inhibitor therapy achieves response rates of 60–75% and median overall survival of 26–27 months, compared to 9–10 months with older chemotherapy.

Adjuvant therapy for stage III: For patients whose melanoma reached lymph nodes and was removed surgically, adjuvant (preventive) immunotherapy reduces recurrence risk by 50% and improves two-year survival by 15–20% compared to watchful waiting.

When to See a Dermatologist

  • You notice a mole or spot that is growing, changing color, or looks different from others
  • You have had any skin cancer before — regular follow-up is essential
  • You have a family history of melanoma
  • You have received a skin cancer diagnosis and want to understand your prognosis and treatment options
  • You have many moles, especially unusual-looking ones

Frequently Asked Questions

What does my five-year survival rate actually mean?

It means the percentage of people with the same type and stage of cancer who are alive five years after diagnosis. It does not mean you will die at five years — many people live decades beyond that point. And the statistic reflects averages from patients diagnosed years ago; modern treatments often produce better results than older data suggest.

Has melanoma survival really improved that much in recent years?

Yes — substantially. Stage IV melanoma went from a median survival of less than one year to two-year survival rates of 35–50% with immunotherapy. For some patients, these responses last for many years and may represent a functional cure. This is one of the great success stories in modern oncology.

Does the thickness of my melanoma determine my chances?

It is the strongest single prognostic factor. A melanoma thinner than 0.8 mm (stage IA) has a 97% five-year survival. A melanoma thicker than 4 mm (stage IIC) has a 53% five-year survival. This is why early detection matters so much — catching melanoma when it is thin is the most reliable way to achieve a cure.

Is basal cell carcinoma curable?

In nearly all cases, yes. BCC has less than a 0.5% disease-specific mortality. Standard treatments achieve cure rates above 95%. Even locally advanced BCC now has effective systemic treatment options (hedgehog inhibitors, immunotherapy).

References

  1. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer 8th edition cancer staging system. CA Cancer J Clin. 2017;67(6):472-492.
  2. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535-1546.
  3. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-1355.
  4. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3622-3632.
  5. Coit DG, Thompson JA, Algazi A, et al. Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(4):367-402.

Trusted Resources

Always consult a board-certified dermatologist or oncologist about your individual skin cancer diagnosis and prognosis. Survival statistics describe populations, not individuals — your doctor can give you the most relevant information for your specific situation.